3rd Edition of
International Ophthalmology Conference
March 10-12, 2025 | Rome, Italy
Primary and Secondary Eye Care
Primary eye care (PEC) is a comprehensive term that encompasses the use of primary health care to avoid potentially blinding eye illnesses (PHC). PEC encompasses the identification of people with treatable causes of blindness, as well as the diagnosis and treatment of common eye conditions, notably those that cause an acute red eye. Primary eye care is a crucial component of blindness prevention in all communities and regions of the world. Only those who present to secondary and tertiary facilities will be diagnosed and treated without basic eye care, and little will be accomplished in terms of prevention. Acute care is required treatment for a short period of time due to a brief but serious illness, injury, or other eye health problem. At the secondary level, such as hospitals, ailments such as cataract, glaucoma, and trachoma are managed.
- Diagnostic Eye Camps
- Eye Donation Awareness Programs
- Preventable Causes of Blindness
John David Bullock
Wright State University, United States
Minckler Don S
UCI Gavin Herbert Eye Institute, United States
Kasra Rezaei
University of Washington, United States
Dhruva Drew Gupta
Harvard Medical School, United States
Nour Abou Shousha
Harvard Medical School, United States
George HH Beiko
McMaster Univeresity, Canada
Mustafa Al Ghazi
University Hospital of Wales, United KingdomSubmit your abstract Today
Title : Optic nerve orthograde axonal transport in abusive head trauma suspects
Minckler Don S, UCI Gavin Herbert Eye Institute, United States
Title : Eyes and guts connection: Microbiomes and their role in ocular health
Edward Charles Kondrot, Healing the Eye Wellness Center, United States
Title : Ultra-Widefield protocol enhances automated classification of diabetic retinopathy severity with OCT angiography
Kasra Rezaei, University of Washington, United States
Title : Why was Leonhard Euler blind?
John David Bullock, Wright State University, United States
Title : Lumevoq gene therapy in leber hereditary optic neuropathy
Magali Taiel, GenSight Biologics, France
Title : Developing resilience-based treatments for glaucoma
Simon John, Columbia University, United States